ATE347361T1 - Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen - Google Patents
Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungenInfo
- Publication number
- ATE347361T1 ATE347361T1 AT02740638T AT02740638T ATE347361T1 AT E347361 T1 ATE347361 T1 AT E347361T1 AT 02740638 T AT02740638 T AT 02740638T AT 02740638 T AT02740638 T AT 02740638T AT E347361 T1 ATE347361 T1 AT E347361T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- combination
- tiotropium
- inhalation
- diseases
- Prior art date
Links
- 230000000414 obstructive effect Effects 0.000 title abstract 3
- 229940110309 tiotropium Drugs 0.000 title abstract 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 2
- 239000000812 cholinergic antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940112141 dry powder inhaler Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229960000257 tiotropium bromide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29355501P | 2001-05-25 | 2001-05-25 | |
| US30384501P | 2001-07-09 | 2001-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE347361T1 true ATE347361T1 (de) | 2006-12-15 |
Family
ID=26968011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02740638T ATE347361T1 (de) | 2001-05-25 | 2002-05-23 | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1397135B1 (enExample) |
| JP (1) | JP2004530705A (enExample) |
| AT (1) | ATE347361T1 (enExample) |
| AU (1) | AU2002314102A1 (enExample) |
| CA (1) | CA2448363A1 (enExample) |
| DE (1) | DE60216588T2 (enExample) |
| ES (1) | ES2276942T3 (enExample) |
| MX (1) | MXPA03010791A (enExample) |
| WO (1) | WO2002096423A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| PT1610787E (pt) * | 2003-03-28 | 2008-04-23 | Nycomed Gmbh | Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias |
| JP2006523674A (ja) * | 2003-04-18 | 2006-10-19 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法 |
| WO2004103407A2 (en) * | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| WO2005013993A1 (en) * | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| EP1504756A1 (en) * | 2003-08-06 | 2005-02-09 | Kyowa Hakko Kogyo Co., Ltd | Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| ES2413011T3 (es) | 2004-02-06 | 2013-07-15 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
| CA2550848C (en) * | 2004-02-06 | 2013-02-26 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| AU2005210086A1 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| JP2007523117A (ja) * | 2004-02-20 | 2007-08-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬及びｐｅｇｓｕｎｅｒｃｅｐｔを基にした新規な医薬組成物 |
| US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| RU2385156C2 (ru) * | 2004-05-31 | 2010-03-27 | Лабораториос Альмираль С.А. | Комбинации, содержащие антимускариновые средства и кортикостероиды |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| SI1863476T1 (sl) | 2005-03-16 | 2016-05-31 | Meda Pharma Gmbh & Co. Kg | Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni |
| KR101278011B1 (ko) * | 2005-04-28 | 2013-06-27 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 만성 폐쇄성 폐질환 치료제 |
| DE102005035112A1 (de) * | 2005-07-27 | 2007-02-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Verfahren zur Herstellung von Tiotropiumsalzen unter Anwendung von in organischen Lösungsmitteln löslichen N-Methylscopiniumsalzen |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| PL1971369T3 (pl) | 2005-12-21 | 2010-01-29 | Meda Pharma Gmbh & Co Kg | Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP1905440A1 (de) * | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2765015C (en) | 2009-06-18 | 2020-05-05 | Concert Pharmaceuticals, Inc. | Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9709897A (es) * | 1995-06-06 | 1998-03-31 | Pfizer | 5-6-dihidro-9h-pirazol[3,4-c]-1,2,4-triazol[4,3-a]piridinas triciclicas y el uso de las mismas. |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
-
2002
- 2002-05-23 WO PCT/EP2002/005643 patent/WO2002096423A2/en not_active Ceased
- 2002-05-23 MX MXPA03010791A patent/MXPA03010791A/es unknown
- 2002-05-23 DE DE60216588T patent/DE60216588T2/de not_active Expired - Lifetime
- 2002-05-23 JP JP2002592933A patent/JP2004530705A/ja active Pending
- 2002-05-23 CA CA002448363A patent/CA2448363A1/en not_active Abandoned
- 2002-05-23 ES ES02740638T patent/ES2276942T3/es not_active Expired - Lifetime
- 2002-05-23 AU AU2002314102A patent/AU2002314102A1/en not_active Abandoned
- 2002-05-23 EP EP02740638A patent/EP1397135B1/en not_active Expired - Lifetime
- 2002-05-23 AT AT02740638T patent/ATE347361T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2276942T3 (es) | 2007-07-01 |
| JP2004530705A (ja) | 2004-10-07 |
| EP1397135B1 (en) | 2006-12-06 |
| MXPA03010791A (es) | 2004-03-02 |
| AU2002314102A1 (en) | 2002-12-09 |
| DE60216588T2 (de) | 2007-09-20 |
| WO2002096423A3 (en) | 2003-02-06 |
| DE60216588D1 (de) | 2007-01-18 |
| CA2448363A1 (en) | 2002-12-05 |
| WO2002096423A2 (en) | 2002-12-05 |
| EP1397135A2 (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60216588D1 (de) | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| MXPA03010731A (es) | Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas. | |
| MXPA03010797A (es) | Combinacion de agonista del receptor d2 de dopamina y tiotropio o derivados del mismo para tratamiento de enfermedades obstructivas de vias respiratorias y otras de tipo inflamatorio. | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| JP2016040316A5 (enExample) | ||
| CA2474479A1 (en) | Composition for inhalation | |
| WO2002078675A3 (en) | Particles for inhalation having sustained release properties | |
| EA200100338A1 (ru) | Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента | |
| MY143517A (en) | Formoterol superfine formulation | |
| ATE357222T1 (de) | Hochwirksame verabreichung eines aerosols mit hoher therapeutischer masse | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| SI9200403B (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
| CN101244063A (zh) | 包含高效长效β2－激动剂和其它活性成分的药物组合物 | |
| BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
| MXPA05009629A (es) | Composiciones que contienen trospio. | |
| CA2425489A1 (en) | Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis | |
| WO2004012653A3 (en) | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof | |
| MX2023003754A (es) | Formulacion farmaceutica para inhalador presurizado de dosis medidas. | |
| AP2002002624A0 (en) | Use of a combination of compounds in a dry powder inhaler. | |
| MY137249A (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| NO20051463L (no) | Inhaleringssammensetninger med hoy legemiddelandel | |
| RU2014144145A (ru) | Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат | |
| WO2005110052A3 (en) | The use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1397135 Country of ref document: EP |